Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities

Leukemia volume 21, pages 37–43 (2007)Cite this article

Abstract

Diffuse large B-cell lymphoma (DLBCL) as defined by the World Health Organization (WHO) classification is clinically, morphologically and genetically a heterogeneous group of malignant proliferations of large lymphoid B cells. Over the last 6 years, several studies have been published improving our understanding of these lymphomas. These studies analyzed DLBCL by their gene expression profile, provided further information on some of the variants of DLBCL listed in the WHO classification and stressed the impact of the site of origin of these tumors. This review summarizes these recent data and explores their impact on the recognition of new clinicopathological lymphoma entities.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Stansfeld AG, Diebold J, Noel H, Kapanci Y, Rilke F, Kelenyi G et al. Updated Kiel classification for lymphomas. Lancet 1988; 1: 292–293.

    Article  CAS  PubMed  Google Scholar 

  2. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112–2135.

  3. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392.

    CAS  PubMed  Google Scholar 

  4. Harris NL . A practical approach to the pathology of lymphoid neoplasms: a revised European-American classification from the International Lymphoma Study Group. Important Adv Oncol 1995; 12: 111–140.

    Google Scholar 

  5. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J . Lymphoma classification – from controversy to consensus: the R.E.A.L. and WHO Classification of lymphoid neoplasms. Ann Oncol 2000; 11: 3–10.

    Article  PubMed  Google Scholar 

  6. Gatter KC, Warnke RA . Diffuse large B-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001, pp 171–174.

    Google Scholar 

  7. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New Engl J Med 2002; 346: 1937–1947.

    Article  PubMed  Google Scholar 

  8. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511.

    Article  CAS  PubMed  Google Scholar 

  9. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994.

  10. Atkins CD . A predictive model for non-Hodgkin's lymphoma. N Engl J Med 1994; 330: 574–575.

    Article  CAS  PubMed  Google Scholar 

  11. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RCT et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68–74.

    Article  CAS  PubMed  Google Scholar 

  12. Huang JZ, Sanger WG, Greiner TC, Staudt LM, Weisenburger DD, Pickering DL et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002; 99: 2285–2290.

    Article  CAS  PubMed  Google Scholar 

  13. Iqbal J, Sanger WG, Horsman DE, Rosenwald A, Pickering DL, Dave B et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol 2004; 165: 159–166.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Bea S, Colomo L, Lopez-Guillermo A, Salaverria I, Puig X, Pinyol M et al. Clinicopathological significance and prognostic value of chomosomal imbalances in diffuse large B-cell lymphomas. J Clin Oncol 2004; 22: 3498–3506.

    Article  CAS  PubMed  Google Scholar 

  15. Bea S, Zettle A, Wright G, Salaverria I, Jehn P . Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005; 106: 3183–3190.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Pasqualucci L, Compagno M, Houldsworth J, Monti S, Grunn A, Nandula SV et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 2006; 203: 311–317.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Tam W, Gomez M, Chadburn A, Lee JW, Chan WC, Knowles DM . Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood 2006; 107: 4090–4100.

    Article  CAS  PubMed  Google Scholar 

  18. Oschlies I, Klapper W, Zimmermann M, Krams M, Wacker HH, Burkhardt B et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood 2006; 107: 4047–4052.

    Article  CAS  PubMed  Google Scholar 

  19. Barrans SL, Carter I, Owen RG, Davies FE, Patmore RD, Haynes AP et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99: 1136–1143.

    Article  CAS  PubMed  Google Scholar 

  20. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282.

    Article  CAS  PubMed  Google Scholar 

  21. Chang CC, McClintock S, Cleveland RP, Trzpuc T, Vesole DH, Logan B et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 2004; 28: 464–470.

    Article  PubMed  Google Scholar 

  22. McCluggage WG, Catherwood M, Alexander HD, McBride HA, Smith MEF, Morris TCM . Immunohistochemical expression of CD10 and t(14 ; 18) chromosomal translocation may be indicators of follicle centre cell origin in nodal diffuse large B-cell lymphoma. Histopathology 2002; 41: 414–420.

    Article  CAS  PubMed  Google Scholar 

  23. Ohshima K, Kawasaki C, Muta H, Muta K, Deyev V, Haraoka S et al. CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology 2001; 39: 156–162.

    Article  CAS  PubMed  Google Scholar 

  24. Pittaluga S, Ayoubi TA, Wlodarska I, Stul M, Cassiman JJ, Mecucci C et al. BCL-6 expression in reactive lymphoid tissue and in B-cell non-Hodgkin's lymphomas. J Pathol 1996; 179: 145–150.

    Article  CAS  PubMed  Google Scholar 

  25. Skinnider BF, Horsman DE, Dupuis B, Gascoyne RD . Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. Hum Pathol 1999; 30: 803–808.

    Article  CAS  PubMed  Google Scholar 

  26. Colomo L, Lopez-Guillermo A, Perales M, Rives S, Martinez A, Bosch F et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101: 78–84.

    Article  CAS  PubMed  Google Scholar 

  27. Falini B, Fizzotti M, Pucciarini A, Bigerna B, Marafioti T, Gambacorta M et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000; 95: 2084–2092.

    CAS  PubMed  Google Scholar 

  28. De Paepe P, Achten R, Verhoef G, Wlodarska I, Stul M, Vanhentenrijk V et al. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. J Clin Oncol 2005; 23: 7060–7068.

    Article  PubMed  Google Scholar 

  29. Monni O, Joensuu H, Franssila K, Klefstrom J, Alitalo K, Knuutila S . BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood 1997; 90: 1168–1174.

    CAS  PubMed  Google Scholar 

  30. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90: 244–251.

    CAS  PubMed  Google Scholar 

  31. Hill ME, MacLennan KA, Cunningham DC, Vaughan HB, Burke M, Clarke P et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood 1996; 88: 1046–1051.

    CAS  PubMed  Google Scholar 

  32. Iqbal J, Neppalli VT, Wright G, Dave BJ, Horsman DE, Rosenwald A et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 961–968.

    Article  CAS  PubMed  Google Scholar 

  33. Muris JJ, Meijer CJ, Vos W, van Krieken JH, Jiwa NM, Ossenkoppele GJ et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol 2006; 208: 714–723.

    Article  CAS  PubMed  Google Scholar 

  34. Carbone A, Gloghini A, Libra M, Gasparotto D, Navolanic PM, Spina M et al. A spindle cell variant of diffuse large B-cell lymphoma possesses genotypic and phenotypic markers characteristic of a germinal center B-cell origin. Mod Pathol 2006; 19: 299–306.

    Article  CAS  PubMed  Google Scholar 

  35. Kaestner KH, Knochel W, Martinez DE . Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev 2000; 14: 142–146.

    CAS  PubMed  Google Scholar 

  36. Banham AH, Beasley N, Campo E, Fernandez PL, Fidler C, Gatter K et al. The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res 2001; 61: 8820–8829.

    CAS  PubMed  Google Scholar 

  37. Banham AH, Connors JM, Brown PJ, Cordell JL, Ott G, Sreenivasan G et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 2005; 11: 1065–1072.

    CAS  PubMed  Google Scholar 

  38. Barrans SL, Fenton JA, Banham A, Owen RG, Jack AS . Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004; 104: 2933–2935.

    Article  CAS  PubMed  Google Scholar 

  39. Wlodarska I, Veyt E, De Paepe P, Vandenberghe P, Nooijen P, Theate I et al. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 2005; 19: 1299–1305.

    Article  CAS  PubMed  Google Scholar 

  40. Sagaert X, de Paepe P, Libbrecht L, Vanhentenrijk V, Verhoef G, Thomas J et al. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 2490–2497.

    Article  CAS  PubMed  Google Scholar 

  41. Adam P, Katzenberger T, Seeberger H, Gattenlohner S, Wolf J, Steinlein C et al. A case of a diffuse large B-cell lymphoma of plasmablastic type associated with the t(2;5)(p23;q35) chromosome translocation. Am J Surg Pathol 2003; 27: 1473–1476.

    Article  PubMed  Google Scholar 

  42. Chikatsu N, Kojima H, Suzukawa K, Shinagawa A, Nagasawa T, Ozawa H et al. ALK+, CD30-. Mod Pathol 2003; 16: 828–832.

    Article  PubMed  Google Scholar 

  43. De Paepe P, Baens M, van Krieken H, Verhasselt B, Stul M, Simons A et al. ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood 2003; 102: 2638–2641.

    Article  CAS  PubMed  Google Scholar 

  44. Gascoyne RD, Lamant L, Martin-Subero JI, Lestou VS, Harris NL, Muller-Hermelink HK et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood 2003; 102: 2568–2573.

    Article  CAS  PubMed  Google Scholar 

  45. McManus DT, Catherwood MA, Carey PD, Cuthbert RJ, Alexander HD . ALK-positive diffuse large B-cell lymphoma of the stomach associated with a clathrin-ALK rearrangement. Hum Pathol 2004; 35: 1285–1288.

    Article  CAS  PubMed  Google Scholar 

  46. Onciu M, Behm FG, Downing JR, Shurtleff SA, Raimondi SC, Ma Z et al. ALK-positive plasmablastic B-cell lymphoma with expression of the NPM-ALK fusion transcript: report of 2 cases. Blood 2003; 102: 2642–2644.

    Article  CAS  PubMed  Google Scholar 

  47. Rudzki Z, Rucinska M, Jurczak W, Skotnicki AB, Maramorosz-Kurianowicz M, Mruk A et al. ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review. Pol J Pathol 2005; 56: 37–45.

    PubMed  Google Scholar 

  48. Bridge JA, Kanamori M, Ma Z, Pickering D, Hill DA, Lydiatt W et al. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol 2001; 159: 411–415.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Cheuk W, Chan JK . Timely topic: anaplastic lymphoma kinase (ALK) spreads its influence. Pathology 2001; 33: 7–12.

    Article  CAS  PubMed  Google Scholar 

  50. Cools J, Wlodarska I, Somers R, Mentens N, Pedeutour F, Maes B et al. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2002; 34: 354–362.

    Article  CAS  PubMed  Google Scholar 

  51. Duyster J, Bai RY, Morris SW . Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 2001; 20: 5623–5637.

    Article  CAS  PubMed  Google Scholar 

  52. Delsol G, Lamant L, Mariame B, Pulford K, Dastugue N, Brousset P et al. A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. Blood 1997; 89: 1483–1490.

    CAS  PubMed  Google Scholar 

  53. Jaffe ES, Gonzalez CL, Medeiros LJ, Raffeld M . T-cell-rich B-cell lymphomas. Am J Surg Pathol 1991; 15: 491–492.

    Article  CAS  PubMed  Google Scholar 

  54. Delabie J, Vandenberghe E, Kennes C, Verhoef G, Foschini MP, Stul M et al. Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype. Am J Surg Pathol 1992; 16: 37–48.

    Article  CAS  PubMed  Google Scholar 

  55. Boudova L, Torlakovic E, Delabie J, Reimer P, Pfistner B, Wiedenmann S et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood 2003; 102: 3753–3758.

    Article  CAS  PubMed  Google Scholar 

  56. Achten R, Verhoef G, Vanuytsel L, De Wolf-Peeters C . Histiocyte-rich, T-cell-rich B-cell lymphoma: a distinct diffuse large B-cell lymphoma subtype showing characteristic morphologic and immunophenotypic features. Histopathology 2002; 40: 31–45.

    Article  PubMed  Google Scholar 

  57. Achten R, Verhoef G, Vanuytsel L, De Wolf-Peeters C . T-cell/histiocyte-rich large B-cell lymphoma: a distinct clinicopathologic entity. J Clin Oncol 2002; 20: 1269–1277.

    CAS  PubMed  Google Scholar 

  58. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105: 1851–1861.

    Article  CAS  PubMed  Google Scholar 

  59. Nakatsuka S, Yao M, Hoshida Y, Yamamoto S, Iuchi K, Aozasa K . Pyothorax-associated lymphoma: a review of 106 cases. J Clin Oncol 2002; 20: 4255–4260.

    Article  PubMed  Google Scholar 

  60. Petitjean B, Jardin F, Joly B, Martin-Garcia N, Tilly H, Picquenot JM et al. Pyothorax-associated lymphoma: a peculiar clinicopathologic entity derived from B cells at late stage of differentiation and with occasional aberrant dual B- and T-cell phenotype. Am J Surg Pathol 2002; 26: 724–732.

    Article  PubMed  Google Scholar 

  61. Carbone A, Gloghini A . AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol 2005; 130: 662–670.

    Article  CAS  PubMed  Google Scholar 

  62. Levine AM . AIDS-related lymphoma. Semin Oncol Nurs 2006; 22: 80–89.

    Article  PubMed  Google Scholar 

  63. Teruya-Feldstein J . Diffuse large B-cell lymphomas with plasmablastic differentiation. Curr Oncol Rep 2005; 7: 357–363.

    Article  CAS  PubMed  Google Scholar 

  64. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768–3785.

    Article  CAS  PubMed  Google Scholar 

  65. Hoefnagel JJ, Dijkman R, Basso K, Jansen PM, Hallermann C, Willemze R et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 2005; 105: 3671–3678.

    Article  CAS  PubMed  Google Scholar 

  66. Lin CH, Kuo KT, Chuang SS, Kuo SH, Chang JH, Chang KC et al. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin. Clin Cancer Res 2006; 12: 1152–1156.

    Article  CAS  PubMed  Google Scholar 

  67. Braaten KM, Betensky RA, de Leval L, Okada Y, Hochberg FH, Louis DN et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 2003; 9: 1063–1069.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, AZ St-Jan AV, Brugge, Belgium

    P De Paepe

  2. Department of Pathology, Division of Morphology and Molecular Pathology, Catholic University Leuven, Leuven, Belgium

    C De Wolf-Peeters

Authors
  1. P De Paepe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C De Wolf-Peeters
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P De Paepe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Paepe, P., De Wolf-Peeters, C. Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia 21, 37–43 (2007). https://doi.org/10.1038/sj.leu.2404449

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404449

Keywords

This article is cited by

Search

Advanced search

Quick links